Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
- Conditions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 88
- Registration Number
- NCT00068744
- Locations
- 🇷🇸
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
🇧🇪Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium
🇧🇪Cazk Groeninghe - Campus Maria's Voorzienigheid, Kortrijk, Belgium
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00068575
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 61
- Registration Number
- NCT00068406
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
🇺🇸Gynecologic Oncology of Indiana, Indianapolis, Indiana, United States
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
- Conditions
- First Posted Date
- 2003-09-09
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00016341
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
- Conditions
- First Posted Date
- 2003-09-09
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00016874
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva
- Conditions
- First Posted Date
- 2003-09-03
- Last Posted Date
- 2013-06-10
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00006096
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer
- Conditions
- Locations
- 🇬🇧
Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇭🇺National Institute of Oncology, Budapest, Hungary
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00066742
- Locations
- 🇺🇸
Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States
Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 19
- Registration Number
- NCT00066482
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 72
- Registration Number
- NCT00066222
- Locations
- 🇺🇸
Howard Community Hospital at Howard Regional Health System, Kokomo, Indiana, United States
🇺🇸Kewanee Hospital, Kewanee, Illinois, United States
🇺🇸OSF St. Francis Medical Center, Peoria, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.